Company / Free Cash Flow
Astria Therapeutics, Inc. Free Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$81.5M
FY2024
5-year range
-$81.5M / -$30.2M
FY2020-FY2024
Trend
-19.1%
vs FY2023
Sector context
#97 of 194
Health Care
What the data says
At -$82M, Astria Therapeutics, Inc.'s free cash flow ranks #97 of 194 in the Health Care sector. Free Cash Flow has declined for 3 consecutive years, from -$30M in FY2021 to -$82M in FY2024.
Based on SEC 10-K filings.
-$82M in FY2024.
Declined from -$44M to -$82M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#97 of 194 in Health CareTop 50% of 194This company -$81.5M Sector average $470.6M
▼
-117.3% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s free cash flow has declined for 3 consecutive years.
- In FY2024, free cash flow decreased 19.1% year-over-year.
- Ranks #97 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$81.5M | -19.1% |
| FY2023 | -$68.5M | -57.0% |
| FY2022 | -$43.6M | -44.6% |
| FY2021 | -$30.2M | +7.2% |
| FY2020 | -$32.5M | -22.3% |
| FY2019 | -$26.6M | - |
| FY2018 | - | - |
| FY2017 | -$26.9M | +19.3% |
| FY2016 | -$33.3M | -10.3% |
| FY2015 | -$30.2M | -46.4% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026